IXICO wins £1.3 million in Alzheimer's and Huntington's contracts

IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the neuroscience imaging and analytics group, has secured a contract win and a contract extension worth a combined £1.3 million over two years. The London-based company will provide amyloid PET imaging analytics to validate a new blood-based biomarker test for Alzheimer's disease on behalf of a global diagnostics and life sciences company, with the work aimed at supporting FDA regulatory clearance.